• DSGT selected as fleet-management solution provider for new golf courses.
• Contracts include servicing and maintenance fees, which provide ongoing continuous monthly revenue.
• CEO reports continued sales records, progress in Vantage Tag and Imperium Motors divisions.

DSG Global (OTCQB: DSGT), an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors, and its Vantage Tag System (“VTS”) have been selected as the fleet-management solution provider for 15 new golf courses (https://ibn.fm/jvVhm). The contracts for the courses, which are located in the United States and abroad, total almost $988,000 and provide an ongoing revenue stream for DSGT from service and maintenance agreements. “There continues to be significant interest in our unique electronic tracking and fleet-management solutions as golf courses worldwide recognize the value of our products,” said Pat Parenti, senior vice president of global sales at Vantage Tag Systems. “The contracts include a fee for servicing and maintenance, which will provide ongoing continuous monthly revenue. “Once the new Infinity screens are available in July, we anticipate orders to accelerate even further,” Parenti continued. “Our sales growth is related to being able to custom-fit systems to the courses’ needs and budgets and by adding seasoned sales professionals on the East and West Coasts and in the Midwest and southern regions of the U.S.” According to the company’s announcement, the new contracts, which were received during Q2 2021, include 1,040 total units of the VTS Infinity, Text and Tag Systems. In addition, Vantage Tag will be introducing the new Infinity 10-inch display screen by mid-September. The new screen will feature updated software with enhanced features. The company plans to install the systems as inventory arrives, with completion slated for this summer. These new orders do not include orders previously received during fiscal year 2021, which are all in the process of being installed. Vantage Tag Systems provides patented electronic tracking systems and fleet-management solutions to golf courses and other avenues that allow for remote management of a course’s fleet of golf carts, turf equipment and utility vehicles. “The company continues to break sales records in Vantage Tag and continued progress with Imperium Motors automotive division,” said DSG Global CEO Robert Silzer. “Our backlog of installations at dozens of golf courses and pre-orders and deliveries of electric vehicles will keep us extremely busy this summer.” DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the VTS brand, the company is moving quickly with road-ready electric vehicles for sale in the first quarter of 2021 through its Imperium Motor Company subsidiary. For more information, visit the company’s website at www.DSGTglobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

• “Private Label” division will be the sixth distribution channel for HempFusion and its family of products
• The 10 SKU deal totals approximately $250,000 and is expected to double in revenue size in 2021 and quadruple in 2022
• Company will be expanding its Topeka, Kansas facility to accommodate orders of this magnitude, requiring additional equipment and human capital
• Research and development teams are currently working with an additional 30 products under development for the HempFusion and family of brands

HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) recently announced that a leading national and publicly traded grocery retailer has awarded the health and wellness company a 10 SKU private label deal. The deal marks the official launch of the “Private Label” division, which will be the company’s sixth distribution channel, and the initial order totals approximately $250,000. It is scheduled to ship in July 2021 (https://ibn.fm/eOzEX). The retailer, whose name was not disclosed due to existing non-disclosure obligations, represents a significant opportunity for the newly launched Private Label division. The 10 SKU deal was primarily due to the performance of HempFusion and its family of products within the retailer’s current distribution network. “We anticipate that this initial $250,000 order is just the beginning and pending sell-through velocity and distribution, we expect this account to generate north of $500,000 for HempFusion in 2021 and upwards of $1,000,000 or more in 2022,” Jon Visser, HempFusion’s Chief Revenue Officer, said. Additionally, Co-Founder and CEO Jason Mitchell, N.D., added that the company is honored to receive this award and looks forward to “how this has the potential to significantly contribute to the overall success of this particular retailer and HempFusion and its family of brands.” To fulfill current and future orders of this magnitude, HempFusion is investing in additional structural support at its distribution facility in Topeka, Kansas. The expansion will include investments in additional equipment and human capital to ensure that the distribution is efficient. The current family of brands distributed by HempFusion Wellness includes HempFusion, Probulin Probiotics, Biome Research, and HF Labs. These products are distributed to approximately 4,000 retail locations in the United States and select international locations. The company’s current product portfolio consists of 48 SKUs that include tinctures, proprietary FDA Drug Listed Over-The-Counter (“OTC”) Topicals, Doctor and Practitioner lines, and much more. There are also an additional 30 products that are under development, which is the primary focus of the company’s research and development efforts. Probulin Probiotics is HempFusion’s wholly owned subsidiary, one of the fastest-growing probiotics brands in the United States. The HempFusion focus for CBD is from the soil to the oil. Not all CBD is created equal, which is why HempFusion uses farming practices and extraction processes that result in a far superior whole food hemp extract. Grown in Europe to EU’s highest standards, HempFusion uses only five select, DNA-verified heirloom hemp strains. The company’s oil extraction uses a proprietary solvent-free CO2 method that yields CBD in a richer, purer oil that contains a higher content of the wide variety of other beneficial cannabinoids and plant compounds. Finally, HempFusion tests all products using an ISO-certified, independent laboratory to identify the cannabinoid and terpene profile, and confirm its organic farming practices have left each product free of      herbicides, pesticides, and heavy metals. All of these reports are available to the public, and the batch report of each product sold is available to the consumer via a QR code on the package. Leveraging this unique approach and product offering, the company is uniquely positioned to seize current and future growth opportunities on both the cannabidiol and probiotics markets. The global cannabidiol market size was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% during the forecast period of 2021 to 2028, resulting in a market size of approximately $13.4 billion in 2028 (https://ibn.fm/29Rj2). The size of the global probiotics market is also set to expand, from $48.38 billion in 2018 to about $77.09 billion by 2025, expanding at a CAGR of 6.9% during the forecast period (https://ibn.fm/9lFEn). For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• The global Esports industry has nearly doubled in the past 6 years—to a projected audience of 646 million in 2023
• Latin America is one of the fastest growing Esports markets in the world: Mobius has a foothold in the top two countries: Mexico and Brazil
• The mobile gaming segment will make up 45% of the global gaming market this year

Mobius Interactive, an online gaming operator that launched with three diverse brands during the pandemic of 2020, is leading with their Esports product – taking full advantage of the rapidly expanding market in global entertainment. Over a six-year period, the global Esports audience is on pace to nearly double its audience – to 646 million in 2023. More and more, people are accessing this exciting and expanding worldwide gaming phenomenon through their mobile devices. For Esports, the mobile component reduces barriers—offering expanded access for gamers and fans. Mobility has become vital to any company entering the gaming industry. Mobile gaming will comprise of 45% of the global gaming market this year. This huge increase is partially attributed to the pandemic surge of new mobile gamers at the beginning of 2020, an increase of 46%. Esports provides opportunities beyond gaming alone. What was once confined to in-person arcades and casinos is now a complex digital ecosystem. Esports incorporates gaming, media, pop culture, and commerce. Esports has burst into the mainstream in recent years, aided by the support of major celebrities like Michael Jordan, Drake, and DJ Marshmello, increased coverage from traditional outlets like ESPN, and the breakneck rise in popularity of Fortnite. Live streaming has become more and more popular with online platforms like Twitch and YouTube Gaming, boosting an expanding base and creating an appetite for more. Latin America is one of the fastest-rising Esports markets in the world. This market is expected to reach $42 million by 2023. Mobius Interactive staged their Brazil launch to coincide with their sponsorship of the FIFA World Cup Qualifiers. The flagship brand of Mobius Interactive Ltd., the Mobius.bet brand, will be seen by up to 40 million viewers per match on Globo TV in Brazil. (https://ibn.fm/45BM4). In the Esports market, Brazil is currently ranked fourth globally, and is second to Mexico in Latin America. Mobius Interactive operates in both countries. In 2021, Esports revenue in Brazil is expected to double since 2017. Total gaming revenue in the country is estimated at 1.17 billion U.S. dollars by 2023. Mobius Interactive is committed to creating the ideal customer experience, using real-time CRM systems to ensure the entire player journey is optimized for entertainment. Throughout our three diverse brands Mobius.bet, Club Double, and Aragon Casino, gamification is utilized to enhance the player experience, driving higher levels of interactivity and engagement. Clients earn loyalty rewards and points, benefits that keep them playing longer. Highly-respected and widely-recognized affiliates drive traffic to all the Mobius Interactive brands, building interest and trust among current clients and potential future players. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Battery-powered electric vehicles are set to be a significant demand driver for silver in coming years
• The expected increase in annual silver demand from the electric vehicle sector over the next four years is estimated to equal 10% of 2021’s global silver production
• Excellon Resources is currently executing ongoing precious metals projects in Mexico, Idaho and Germany
• The company recently revealed that its Mexican operations resulted in a 37% YoY increase in silver production as of the fourth quarter of 2020

Fifty grams is slightly more than the weight of an average golf ball, yet it also represents the estimated silver content contained within a battery electric vehicle (“BEV”) (https://ibn.fm/IzGx9). Silver has historically enjoyed widespread usage within the automotive sector, a reflection of its superior electrical conductivity properties, excellent oxide resistance and durability under harsh operating environments. With electric vehicles rapidly rising as a proportion of global automotive sales, the sector is transforming into a powerful demand center for silver, with The Silver Institute forecasting that the automotive industry will absorb nearly 90 million ounces of silver annually by 2025, a significant increase from this year’s anticipated demand of 61 million ounces (1,900t). To put that figure into context, the expected annual demand from the electric vehicle sector is expected to increase over the next four years to over 10 percent of annual global silver production, based on 2021 projections (https://ibn.fm/ZuQCf). The surge in demand should be particularly advantageous for companies such as Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with precious metal projects in Mexico, Idaho and Germany. Silver’s unique properties make it difficult to replace across a wide and growing array of automotive applications; furthermore, and unlike platinum group metals, the use of silver is not concentrated within a single automotive component like a catalytic converter. Rather, silver components can be found across a myriad of vehicular applications, including reversing cameras, automotive lenses, and fuel management systems, making the precious metal relatively harder to substitute. A recent study carried out by The Silver Institute has estimated the average internal combustion engine (“ICE”) vehicle to consume 15-28 grams (0.5-0.9 ounces) of silver, a figure which would increase to 18-34 grams for hybrid vehicles and to 25-50 grams for the average BEV. Notably, that figure does not take into account ancillary services which also require the use of silver, such as the construction of charging stations and charging points for electric vehicles. While silver’s longer-term demand outlook looks bright, driven by surging demand from electric vehicle manufacturers as well as from the solar/photovoltaic industry where silver is a key component utilized in the manufacture of solar cells, sustained growth in silver mine production will necessitate further investment to bring earlier stage projects into production, thereby offsetting losses from reserve depletion and grade decline. Excellon Resources is currently working towards developing a precious metals growth pipeline across a myriad of geographies, including: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho boasting strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany. Excellon has seen particularly promising results from its Platosa Mine located in Durango, Mexico. Over the course of 2020, the company revealed that its Mexican-based mining operations had resulted in a 37 percent year-over-year increase in silver production, with lead output rising by 32 percent and zine production growing by 19 percent (https://ibn.fm/kQwN4). Excellon has also updated the market in April 2021 of the results of further underground expansion and exploration drilling at the Platosa Mine, which resulted in the discovery of additional high-grade silver deposits. As per the company’s announcement, further definition and expansion of the Guadalupe North, 623, NE-1 and NE-1S mantos, with results from underground drilling including:

• 1,293 g/t silver equivalent (“AgEq”) over 6.5 metres (618 g/t Ag, 10.1% Pb and 12.0% Zn) in EX21UG565;
• 1,571 g/t AgEq over 4.6 metres (688 g/t Ag, 14.5% Pb and 14.9% Zn) in EX21UG564; and
• 1,031 g/t AgEq over 4.6 metres (359 g/t Ag, 4.9% Pb and 15.9% Zn) in EX20UG522A, including 1,531 g/t AgEq over 1.3 metres (573 g/t Ag, 8.6% Pb and 21.5% Zn).

With rising environmental awareness and a growing transition away from fossil fuels set to drive further growth of both the electric vehicle and photovoltaic sectors, silver demand and price momentum are expected to continue their ongoing rise in the coming future. Through its various projects and ongoing production momentum, Excellon Resources looks well positioned to capitalize on the precious metal’s renaissance. For more information, visit the company’s website at www.ExcellonResources.com. NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

• The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress
• EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine
• Cybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO

In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it is co-sponsoring a study focused on treating frontline clinicians experiencing COVID-related distress (https://ibn.fm/NvMAo). In addition to co-sponsoring the study, Cybin also announced the development of EMBARK, a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine. “Our nation’s doctors, nurses and clinicians have been shouldering the burden of COVID-19 by taking care of the sickest among us,” said Dr. Alex Belser, Cybin’s chief clinical officer. “They’re experiencing high levels of anxiety, depression and burnout. Now it’s our turn to help them. We are sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID-related distress.” The study, which Cybin will be co-sponsoring in a strategic collaboration with the University of Washington, will be hosted in Seattle, one of the cities hit hardest at the outset of the pandemic, and will be led by Dr. Anthony Back, a recognized leader in the fields of palliative care and oncology. The randomized, placebo-controlled trial of psychedelic-assisted psychotherapy with psilocybin will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals. “There is tremendous potential in a collaboration between the University of Washington and Cybin to move the field forward, and this project is an incredibly valuable initial step towards a productive future,” said Back, who will serve as primary investigator to the clinical trial. Designed to support the initiative, Cybin’s EMBARK model was developed by Belser and PhD candidate Bill Brennan. Cybin noted that the development of EMBARK has been guided by leading process evidence for the clinical efficacy of psychedelic-assisted psychotherapy and demonstrated theories of therapeutic action to support healing. “EMBARK was designed as a transdiagnostic psychotherapy model that can be adapted to address a range of clinical indications and populations,” the company stated. “For more than a year now, frontline clinicians and healthcare professionals have made immeasurable sacrifices to protect public health in their communities,” said Cybin CEO Doug Drysdale. “We consider it an honor and our duty to now help support their own healing processes, post-COVID-19. We are also delighted and proud to launch EMBARK, a ground-breaking psychotherapy model aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics. We look forward to working with and supporting Dr. Anthony Back on this important program.” Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• China-focused communications technology company FingerMotion is riding a wave of optimism following FYE 2020 reporting that showed revenues have nearly reached $17 million and gross profits rose 71 percent
• The company also saw the initial revenues from its new venture into big data, which it expects to become a primary driver of its business profile as it draws on mobile users’ information to power its predictive services
• FingerMotion’s Sapientus platform for predictive services was a huge draw in establishing a landmark agreement with Pacific Life Re-insurance for Pacific Life’s insurtech solutions in China
• Sapientus’ predictive database has the potential to become a powerful B2B resource for other industries as well, including health care, financial services and consumer e-commerce applications

Building on a trajectory of repeated reports of record revenue gains, evolving communications and insurance technology company FingerMotion (OTCQX: FNGR) is anticipating significant growth in mobile phone service sales during the coming year — potentially 20 to 30 percent in SMS short messaging services and as much as 1,000 percent in top-up airtime credit transfers. The company’s focus on rich communication services (“RCS”) and big-data insights in China’s huge marketplace for mobile products has positioned the U.S-based company for growth in the insurtech industry, particularly, where it anticipates acquiring service for more than a billion customers in the Southeast Asian nation. FingerMotion aims to build a communications ecosystem of active users of its innovative applications, drawing on partnerships with Alibaba’s (NYSE: BABA) TMALL sites, plus PinDuoDuo’s (NYSE: PDD) and JD.com’s (NASDAQ: JD) platforms. The company expects to thereby develop its access to users’ data to strengthen its Sapientus database IP, which has already led to a landmark agreement with Pacific Life Re-insurance that will help Pacific Life enhance its insurance solutions among Chinese clients and develop predictive consumer information that can serve as a substitute for a credit score system where a standard for such a system doesn’t already exist. “The Company is rapidly evolving and we saw the first indication of revenue (during the just-concluded fiscal year), albeit small ($33,077), from the Big Data Insights division,” CEO Martin Shen stated in reporting the company’s year-end financial position (https://ibn.fm/R39CC). “We are a technology company and believe our future lies in the Big Data Insights division. By the end of calendar 2021, we expect multiple contracts relating to our Insuretech products.” FingerMotion foresees the possibility of its Sapientus database’s predictive services eventually serving the needs of other market sectors such as health care, financial services and consumer e-commerce applications as well. The FYE 2021 financial results reported an annual gross profit of $1.65 million, which was an increase of $0.68 million or 71 percent compared to FYE 2020. Annual revenues grew 82 percent to $16.68 million from all its sectors. While general and administrative expenses also grew during the year, FingerMotion remains “steadfast in our belief that we will reach profitability in the near future,” Shen stated. The company’s shareholder equity, or its ability to cover its liabilities with its assets, ended the year in positive territory of $2.11 million, which Shen hailed as “a big step forward” for the company in meeting the qualifications for listing with senior exchanges. “For the past two years we have been driving revenue and profitability at the same time,” Shen stated. “We are constantly striving to optimize our resources.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Providing invaluable support to promising startups sets HLTT apart as early-stage companies work to break with tradition, launch their own products
• Playing a strategic role during critical phases of company life-cycles is a key approach that Healthtech is confident will breed increased chances of success
• VarianBio joins MediScan, RevHeart as trio of innovative healthcare technology companies in HLTT portfolio

A new trend is emerging in the world of drug development — a trend that Healthtech Solutions (OTC: HLTT) is intent on leveraging as it focuses on developing a strong portfolio model in biotech and medtech. That commitment to reinventing the incubator model and providing invaluable support to promising startups sets HLTT apart as companies work to break with tradition and launch their own products. “Imagine you’re the leader of a small biopharmaceutical company,” a recent McKinsey & Company article stated. “As your new drug makes good progress through clinical trials, you face a moment of truth: Do you have what it takes to launch your product yourself? Twenty years ago, the answer to that question would almost certainly have been ‘no.’ Small biotechnology and biopharma companies followed a well-worn path for their assets and explored licensing, partnership, and outright acquisition as their means to product launches. But that pattern has shifted over the past decade or so as more small companies decide to launch their products themselves. “Globally, those first-time launchers account for more than a quarter of all new molecular entities submitted to the US FDA since 2016,” the article pointed out. “That share rises to more than a third when including subsequent launches from companies that launched their first product after 2001.” Being a key piece of these first-time launchers in the pharmaceutical industry is a strategic approach that Healthtech is confident will bring success. Most recently, HLTT broadened its portfolio and entered the precision cancer care market when it acquired VarianBio, a company that is developing two preclinical assets: VAR-101 for basal cell carcinoma (“BCC”) and VAR-102 for a variety of solid tumors, including pancreatic, colorectal and NSCLC. VarianBio joins MediScan and RevHeart as a trio of innovative healthcare technology companies benefitting from Healthtech’s commitment to providing experienced leadership, deep insight and valued resources to the biopharmaceuticals space. “Varian Bio is at the leading edge of cancer treatment technology, and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman David Rubin. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.” VarianBio is developing a proprietary atypical protein kinase C iota (aPKCI) inhibitor for the treatment of various tumor types. In addition to the strides the company is making in precision oncology, Healthtech is also developing technology to transform 2D images from a portable ultrasound into digital 3D images with AI/ML interpretation to bring accurate decision making to the bedside. The technology, being developed by subsidiary MediScan, has applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.HealthTechSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• Pure Extracts working on innovative, larger capacity cartridge for vape products, destined for Canadian retail market
• Cartridges to be produced by global manufacturer, will be filled with selection of Pure Extracts’ 30+ proprietary cannabis FSO formulations
• Move towards larger cartridges follows careful assessment of underlying consumer trends by the Company, finding demand for higher capacity vape cartridges to be particularly strong within provincial markets

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms and rapidly emerging psychedelic sector, announced that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has developed and is currently engaging in the production of innovative 1 gram, full spectrum oil (“FSO”), vape cartridges for the Canadian retail market (https://ibn.fm/4tRa6). The CBD vape market has been a beneficiary of strong customer demand as of late, with Data Bridge Market Research forecasting that the sector could be worth as much as $28.05 billion by 2027 (https://ibn.fm/70TBH). CBD oil usage has increased across a range of medical applications, such as the treatment of anxiety and depression, stress relief, diabetes prevention, pain mitigation, the alleviation of cancer symptoms, and even acne reduction. These are all factors singled out by Data Bridge as key drivers underpinning demand growth within the segment. The production of higher capacity vape cartridges for the Canadian retail market has been undertaken by Pure Extracts following close observation of underlying consumer trends. In addition to a change in consumer preferences, Pure Extracts has found demand for larger cartridges to be particularly strong within provincial markets, with the product offering exceptional value to customers while simultaneously generating higher margins for the Company. Pure Extracts’ cartridges will be filled with a selection of some of the Company’s 30+ proprietary cannabis FSO formulations, including Super Lemon Haze, Grand Daddy Purple and GSK. “We are proud to be a leading innovator in the cannabis vape sector,” stated Pure Extracts CEO Ben Nikolaevsky. “The combination of a larger form factor with our exceptional cannabis extracts will definitely build on the loyal following Pure Pulls already has in-place.” The production of the new 510 vape cartridges will be produced by a global manufacturer and adhere to the highest North American test standards. The cartridges have been specifically chosen for the quality of their component parts, their fit and finish, as well as their performance characteristics when paired with Pure Extracts’ oil concentrates. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Alkaline water is emerging segment in $217.7 billion global bottled water market
• BevCanna has partnered with leading U.S. inventory and fulfillment technology platform provider for the launch of TRACE alkaline and mineralized waters in the U.S.
• TRACE is already sold online and at over 3,000 retail locations in Canada, distribution points that will be further increased following separate agreement with top eastern Canada distributor

While the COVID-19 pandemic was keeping people on lockdown, the logistics industry was thriving, as consumers became increasingly familiar with shopping from home. At the same time, the premium bottled water industry continues to gain traction as people seek healthier alternatives to sugar drinks. Those two trends bode well for BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) and its Naturo Group division, which just forged a new partnership to accelerate the launch of its TRACE natural spring alkaline water and plant-based mineralized water into U.S. markets. Alkaline water is an emerging category that has caught consumer attention in the last decade, growing from a $325 million market in 2013 to $631 million in 2017 (https://ibn.fm/ypFho) on a path to contribute billions annually to the broader global bottled water market that Grand View Research believes hit $217.7 billion in 2020 (https://ibn.fm/nuqW9). Regular drinking water has a neutral pH of 7.0. Alkaline water is defined as having a pH of over 7 and under 10. The higher pH is touted to provide a bevy of benefits to the body by neutralizing acidity, which boosts immunity, slows signs of aging, increases energy and even helps ward off serious diseases, like cancer. While acknowledged widely, opponents say the evidence is not clear and requires clinical studies to substantiate. As such, alkaline water manufacturers are careful to not make any claims about health benefits; that is left up to the consumer to decide. Pundits can argue wellbeing benefits, but what is not up for debate is the very real category growth of alkaline water. According to market research firm Zenith Global, 96% of the alkaline water market was generated in just two markets: North America and Japan. Two brands, Core and Essentia, were clear drivers in 44 percent annual growth in North America from 2013-2018. In 2018, Keurig Dr. Pepper shelled out $525 million for Core (https://ibn.fm/izwKB), which was followed by Nestle paying an estimated $1 billion for Essentia (https://ibn.fm/KAG87) to strengthen its functional water portfolio. The burgeoning market is highly fragmented outside of Core and Essentia, putting BevCanna in a strong position to build its TRACE brand. TRACE already enjoys a leadership position within the alkaline and plant-based fulvic and humic mineral category being sold in more than 3,000 Canadian retailers. BevCanna has world-class infrastructure undergirding all its brands, including a 40,000-square-foot, HACCP certified manufacturing facility near Osoyoos, British Columbia with a current bottling capacity of up to 210 million bottles per annum and access to a pristine alkaline spring water aquifer located onsite. TRACE North American distribution and logistics infrastructure should get supercharged thanks to a new partnership with “a leading U.S. inventory and fulfillment technology platform provider.” As often happens, BevCanna is not permitted (at least not yet) to use the new partner’s name for competitive reasons. The company did, though, provide some hints about the unified technology platform and logistics provider, such as it:

• being “recently recognized by Fast Company magazine as one of the World’s Most Innovative Companies;”
• working with “thousands of customers in every vertical, including many Fortune 500 brands;” and
• having “one of the ten largest warehouses networks in the U.S.”

“We’re pleased to be able to leverage this unique logistics systems in the U.S. launch of our TRACE line of products,” said BevCanna President Melise Panetta in the news release on the partnership (https://ibn.fm/RjrB7). “Employing this sophisticated cloud-based platform will allow us to accelerate our launch across the country and ensure seamless delivery of our TRACE products to retailers nation-wide,” she added. BevCanna is aggressively pursuing distribution partners for its TRACE line in domestic and international markets. On Wednesday, June 2, 2021, the company said it also forged an agreement with leading Eastern Canadian wholesaler distributor Koyo Foods Inc. The contract will see Koyo Foods distribute the TRACE line of products to retailers in Ontario and Quebec, with Koyo confirming that it already has received orders from “a number of retailers.” For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration
• Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed
• BRSF’s E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient’s brain activity in a non-intrusive way

Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Biomarkers are essential as they can help improve diagnostic accuracy and thus improve patient outcomes. There are currently 250 biochemical markers about a broad range of the body’s organic systems and how they function, but this approach still remains a challenge for psychiatric disorders. The partnership between Brain Scientific and Ehave is intended to change this (https://ibn.fm/eX4AD). Mental health disorders are affecting more and more people worldwide — it has been estimated that 51.5 million adults (20.6%) experienced mental illness in 2019 in the US alone (https://ibn.fm/6C81O). Psychedelic drugs are increasingly becoming part of mainstream psychiatry conversation. A growing body of evidence indicates that they could be effective for treating a range of mental illnesses, especially when coupled with talking therapy (https://ibn.fm/BW9pa). This breakthrough could potentially have profound implications for a space that has seen few pharmacological advancements over recent decades regarding the treatment of mental disorders affecting millions of people around the world, including depression, anxiety, PTSD, addiction, and more. Still, experts caution that more research is needed. This is where the partnership between Brain Scientific and Ehave can potentially make a difference. The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI and linked data protocols to develop neural net algorithms. As an initial use case, the neural net algorithm would be used to upload an already trained neuronet into a specialized chip, a temporary E-Tattoo, developed by Brain Scientific. Brain Scientific would also contribute to the collaboration by providing its proprietary data signal acquisition technology, NeuroCap, and NeuroEEG. These devices, designed to collect and read brain activity, would be linked to the Ehave platform. Brain Scientific will also provide the training and support needed to operate the installed equipment, the required software, and hardware and will develop and validate products within three months of receiving any specifications from Ehave. As part of the MoU, Ehave’s role would be to acquire real-time patients data from Brain Scientific’s NeuroCap and NeuroEEG and transfer it into a cloud. Both Ehave and Brain Scientific will jointly own the data from this collaboration. In addition, Ehave could seek to leverage its network of partner healthcare providers, including psychiatrists, psychologists, psychotherapists, and general practitioners, to use NeuroCap and NeuroEEG in clinical settings and collect the data about the electrophysiological changes in brain pre, mid and post-psychedelic drug administration. The collaboration could lead to building or partnering with functional labs where NeuroCap and NeuroEEG devices could be deployed to conduct market studies on consumer behavior and psychology and collect data on various brain-related physiological and mental disorders. These labs are likely to start in Australia and could be rolled out in other parts of the world where Ehave has its footprint. With E-Tattoo, an EEG device about the size of a stamp, Brain Scientific allows continuous measurement of patients’ brain activity in a non-intrusive way and with minimal distraction from everyday life. Brain Scientific believes that the future of EEG testing will be based on non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. Graphene, often called the wonder material of the 21st century, could potentially allow the development of smaller electrodes — even thinner than a human hair. The two companies are poised to leverage their unique expertise and work together to make a big step forward in neurological and psychiatric research by utilizing graph-based AI and linked data protocols to help develop biomarkers for psychiatric disorders. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF